{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:39:48Z","timestamp":1793965188136,"version":"4.8.0"},"reference-count":17,"publisher":"American Society of Hematology","issue":"6","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Long-term prophylaxis with a von Willebrand factor (VWF) concentrate is recommended in patients with von Willebrand disease (VWD) who have a history of severe and frequent bleeds. However, data from prospective studies are scarce. WIL-31, a prospective, noncontrolled, international phase 3 trial, investigated the efficacy and safety of Wilate prophylaxis in severe patients with VWD. Male and female patients 6 years or older with VWD types 1, 2 (except 2N), or 3 who had completed a prospective, 6-month, on-demand, run-in study (WIL-29) were eligible to receive Wilate prophylaxis for 12\u00a0months. At baseline, patients (n\u00a0= 33) had a median age of 18 years. Six (18%) patients had severe type 1, 5 (15%) had type 2, and 22 (67%) had type 3 VWD. The primary end point of a &amp;gt;50% reduction in mean total annualized bleeding rate (TABR) with Wilate prophylaxis vs prior on-demand treatment was met; mean TABR during prophylaxis was 5.2, representing an 84.4% reduction. The bleeding reduction was consistent across age, sex, and VWD types. The mean spontaneous ABR was 3.2, representing an 86.9% reduction vs on-demand treatment. During prophylaxis, 10 (30.3%) patients had 0 bleeding events and 15 (45.5%) patients had 0 spontaneous bleeding events. Of 173 BEs, 84.4% were minor and 69.9% treated. No serious adverse events related to study treatment and no thrombotic events were recorded. Overall, WIL-31 showed that Wilate prophylaxis was efficacious and well-tolerated in pediatric and adult patients with VWD of all types. The WIL-29 and WIL-31 trials were registered at www.ClinicalTrials.gov as #NCT04053699 and #NCT04052698, respectively.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011742","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T20:11:35Z","timestamp":1705608695000},"page":"1405-1414","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["von Willebrand factor\/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease"],"prefix":"10.1182","volume":"8","author":[{"suffix":"Jr.","given":"Robert F.","family":"Sidonio","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-2336","authenticated-orcid":false,"given":"Ana","family":"Boban","sequence":"additional","affiliation":[{"name":"2Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb University School of Medicine, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Dubey","sequence":"additional","affiliation":[{"name":"3Communal Nonprofit Enterprise \u201cWestern Ukrainian Specialized Children\u2019s Medical Center\u201d of Lviv Regional Council, Lviv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adlette","family":"Inati","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, NINI Hospital, Tripoli, Lebanon"},{"name":"18Lebanese American University School of Medicine, Byblos, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5170-5965","authenticated-orcid":false,"given":"Csongor","family":"Kiss","sequence":"additional","affiliation":[{"name":"5Division of Pediatric Hematology-Oncology, Department of Pediatrics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Boda","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshko","family":"Lissitchkov","sequence":"additional","affiliation":[{"name":"7Department of Chemotherapy, Hemotherapy and Hereditary Blood Diseases at Clinical Hematology Clinic, Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Nemes","sequence":"additional","affiliation":[{"name":"8Medical Centre of Hungarian Defence Forces, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dzmitry","family":"Novik","sequence":"additional","affiliation":[{"name":"9Government Agency \u201cRepublican Research Center for Radiation Medicine and Human Ecology,\u201d Gomel, Belarus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Peteva","sequence":"additional","affiliation":[{"name":"10Pediatric Clinic of Haematology and Oncology, University Hospital St. Marina-Varna, Varna, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali T.","family":"Taher","sequence":"additional","affiliation":[{"name":"11Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita Arkadevna","family":"Timofeeva","sequence":"additional","affiliation":[{"name":"12Federal State Budgetary Scientific Institution Kirov Scientific-Research Institute of Hematology and Blood Transfusion of Federal Medical and Biological Agency, Kirov, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna V.","family":"Vilchevska","sequence":"additional","affiliation":[{"name":"13National Specialized Children\u2019s Hospital Okhmatdyt, Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Vdovin","sequence":"additional","affiliation":[{"name":"14Morozovskaya Children\u2019s City Clinical Hospital, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Werner","sequence":"additional","affiliation":[{"name":"15Octapharma USA, Paramus, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurd","family":"Knaub","sequence":"additional","affiliation":[{"name":"16Octapharma AG, Lachen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Djambas Khayat","sequence":"additional","affiliation":[{"name":"17Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"issue":"21","key":"2024032513103707200_bib1","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"von Willebrand's disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"2024032513103707200_bib2","doi-asserted-by":"crossref","first-page":"20406207211064064","DOI":"10.1177\/20406207211064064","article-title":"Prophylactic management of patients with von Willebrand disease","volume":"12","author":"Franchini","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"2024032513103707200_bib3","first-page":"45","article-title":"Diagnosis and treatment of von Willebrand disease and rare bleeding disorders","volume":"6","author":"Castaman","year":"2017","journal-title":"J\u00a0Clin Med"},{"issue":"suppl 6","key":"2024032513103707200_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"4","key":"2024032513103707200_bib5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MBC.0000000000000257","article-title":"Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network","volume":"26","author":"Holm","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2024032513103707200_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.thromres.2020.12.030","article-title":"Translating the success of prophylaxis in haemophilia to von Willebrand disease","volume":"199","author":"Miesbach","year":"2021","journal-title":"Thromb Res"},{"key":"2024032513103707200_bib7","doi-asserted-by":"crossref","first-page":"10760296221130334","DOI":"10.1177\/10760296221130334","article-title":"Disease burden in patients with von Willebrand disease potentially eligible for prophylaxis: post hoc analysis of a European cross-sectional study","volume":"28","author":"Du","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"2024032513103707200_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease","volume":"5","author":"Connell","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"2024032513103707200_bib9","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/j.1538-7836.2006.02179.x","article-title":"The von Willebrand disease prophylaxis network: exploring a treatment concept","volume":"4","author":"Berntorp","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"2024032513103707200_bib10","author":"wilate\u00ae","year":"2023"},{"key":"2024032513103707200_bib11","author":"wilate\u00ae","year":"2021"},{"issue":"1","key":"2024032513103707200_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2516.2008.01901.x","article-title":"Treatment and prevention of acute bleedings in von Willebrand disease - efficacy and safety of Wilate\u00ae, a new generation von Willebrand factor\/factor VIII concentrate","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"issue":"5","key":"2024032513103707200_bib13","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.3892\/etm.2016.3144","article-title":"Heavy menstrual bleeding and health-associated quality of life in women with von Willebrand's disease","volume":"11","author":"Govorov","year":"2016","journal-title":"Exp Ther Med"},{"issue":"2","key":"2024032513103707200_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.2021014810","article-title":"Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results","volume":"140","author":"Leebeek","year":"2022","journal-title":"Blood"},{"key":"2024032513103707200_bib15","author":"Vonvendi\u00ae","year":"2022"},{"issue":"1","key":"2024032513103707200_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/ejh.13949","article-title":"Prophylaxis with recombinant von Willebrand factor (rVWF) in patients with type 3 von Willebrand disease (VWD): results of a post hoc analysis from a phase 3 trial","volume":"111","author":"Leebeek","year":"2023","journal-title":"Eur J Haematol"},{"key":"2024032513103707200_bib17","author":"Humate P","year":"2020"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/6\/1405\/2219079\/blooda_adv-2023-011742-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/6\/1405\/2219079\/blooda_adv-2023-011742-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T13:11:11Z","timestamp":1711372271000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/6\/1405\/514639\/von-Willebrand-factor-factor-VIII-concentrate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,3,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011742","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]}}}